Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials.

Phillip J MeasePhilip S HelliwellKasper Fjellhaugen HjulerKyle RaymondIain McInnes

Published in: Annals of the rheumatic diseases (2020)

Brodalumab was associated with rapid and significant improvements in signs and symptoms of PsA versus placebo. Brodalumab was well tolerated, with a safety profile consistent with other interleukin-17 inhibitors.

Keyphrases

phase iii
open label
clinical trial
double blind
placebo controlled
phase ii
prostate cancer
study protocol
randomized controlled trial
physical activity
depressive symptoms